Home > Journals > Panminerva Medica > Past Issues > Panminerva Medica 2020 September;62(3) > Panminerva Medica 2020 September;62(3):131-4

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

ORIGINAL ARTICLE   

Panminerva Medica 2020 September;62(3):131-4

DOI: 10.23736/S0031-0808.19.03795-9

Copyright © 2019 EDIZIONI MINERVA MEDICA

language: English

Exploring the concept of vigor and dys-vigor in men of 50-65 years: effects of Robuvit®

Andrea LEDDA, Morio HOSOI, Maria R. CESARONE, Mark DUGALL, Shu HU, Gianni BELCARO , Claudia MAIONE, Roberto COTELLESE, Beatrice FERAGALLI, Valeria SCIPIONE, Claudia SCIPIONE

IRVINE3 Labs, Department of Medical Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy



BACKGROUND: The aim of this registry study was to evaluate the effects of Robuvit® (extract from oak wood), in otherwise healthy subjects (aged 50 to 65 years) who complained of decreased general vigor. Robuvit® has been shown to be effective in convalescence, chronic fatigue syndrome and post-traumatic stress disorder.
METHODS: The standard management (SM) for this condition included diet, regular daily routines and regular exercise. All subjects had increased oxidative stress (>350 Carr Units) at inclusion. Two groups, SM and SM+Robuvit® supplementation, were formed. Robuvit® was supplemented at a dose of 300 mg/day for 4 weeks. A visual analogue scale line or vigor visual analogue line score of the most common problems associated with a decrease in vigor was used by all included subjects.
RESULTS: Forty subjects were included in the study. 20 in the SM group and 20 in the SM + Robuvit® supplement group. All subjects completed the 4-week study; both groups improved with the health program and under SM. No drop-outs and no side effects were recorded; a very good tolerability for the supplement was reported. At 4 weeks, the scores in Robuvit®-supplemented subjects, were significantly higher for all vigor-related items in comparison with the scores of subjects managed with the SM only (P<0.05). In parallel, oxidative stress (plasma free radicals expressed in Carr units) was statistically lower (P<0.05) in Robuvit®-supplemented subjects than in SM only after 4 weeks.
CONCLUSIONS: The concept of vigor, partially associated with premature aging, decreased level of activity and exercise, a sedentary lifestyle, appears to be a quantifiable entity. Robuvit® supplementation - previously shown to be effective in chronic fatigue syndrome, convalescence, post-mononucleosis, PTSD or in liver failure - improves vigor; further evaluations need to be planned according to the concept of this pilot registry.


KEY WORDS: Fatigue; Robuvit; Oxidative stress

top of page